Papillary Thyroid Carcinoma with Distant Metastases: What to Do When Radioactive Iodine Fails

Clinical scenario

Papillary thyroid carcinoma (PTC) with distant metastases — most commonly to the lungs or bone — is an advanced presentation that typically begins with radioactive iodine (RAI) therapy. When that approach no longer achieves disease control, a structured next-line strategy is required.

Failure condition: when RAI does not achieve its goals

First-line management targets suppression of serum TSH below 0.1 mIU/ml and no structural disease progression on cross-sectional imaging between treatments with radioactive iodine (¹³¹I) after TSH stimulation. When these goals are not met — disease continues to progress despite RAI — the clinical pathway escalates to systemic therapy.

Next-line approach (partial overview)

For RAI-refractory PTC with distant metastases, guideline-recommended management centres on targeted systemic therapy using a multikinase inhibitor as the first-line option, continued until disease response is lost or treatment is no longer tolerated. The full selection criteria, sequencing, and alternative options are defined in the complete protocol.

Treatment goals

Success is assessed by reduction in serum thyroglobulin and the absence of disease progression on imaging, with scheduled reassessment every 3–12 weeks during active systemic treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/annonc/mdz400

Patients with distant metastases should receive 100–200 mCi (3.7–7.4 GBq) of ¹³¹I after TSH stimulation.
Lenvatinib and sorafenib should be considered the standard first-line systemic therapy for RAI-refractory DTC.
MKIs should be continued until the disease progresses, unacceptable toxicities occur or the patient asks to stop treatment.
Reductions in serum Tg are expected in responders, but clinical decisions cannot be based on this parameter alone.
The imaging assessment should be repeated every 3–12 weeks during treatment.

View source ↗